Additional Valerian Safety Data Needed To Gain OTC Status, FDA Says
This article was originally published in The Tan Sheet
Executive Summary
Additional data on valerian's safety must be provided to FDA before the agency can consider including the botanical in the final monograph for OTC nighttime sleep aid drugs, FDA states in an April 7 letter to European-American Phytomedicines Coalition (EAPC) counsel Robert Pinco
You may also be interested in...
Monograph Eligibility To Include U.S. Rx-Only Drugs With Foreign OTC Data
A drug marketed OTC in foreign countries but limited to Rx use in the U.S. could be considered for eligibility in the OTC monograph system under FDA's final rule on "material time, material extent" criteria, published in the Federal Register Jan. 23
VALERIAN MONOGRAPH STATUS AS OTC NIGHTTIME SLEEP AID IS SOUGHT
VALERIAN MONOGRAPH STATUS AS OTC NIGHTTIME SLEEP AID IS SOUGHT, based largely on the ingredient's marketing history in Europe, by the European-American Phytomedicines Coalition in a June 8 citizen petition to FDA. "Adequate data are available to establish that valerian is not a new drug," EAPC maintained, "because it is generally recognized as safe and effective and has been marketed for a material time and to a material extent."
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC